Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi,Hisashi Yamanaka,Toshiyuki Yoneda,Harry K Genant,Satoshi Soen,Désirée Van Der Heijde,Yoshiya Tanaka,Sakae Tanaka,Takaya Nitta,Naoki Okubo

doi:10.1136/annrheumdis-2018-214827

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi, Hisashi Yamanaka + Show 8 more

Open Access

https://doi.org/10.1136/annrheumdis-2018-214827

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Apr 26, 2019
Citations: 106	License type: open-access

Affiliation: Keio University, Tokyo Women's Medical University, Osaka University, University of California, San Francisco, Kindai University, Leiden University Medical Center, University of Occupational and Environmental Health Japan, The University of Tokyo, Daiichi-Sankyo (Japan)

#Conventional Synthetic Disease-modifying Antirheumatic Drug #Placebo Group + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre, randomised,...

Full Text